New York, NY - Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer and may lead to many unnecessary biopsies. The new study of more than 5,000 men was published online ...
MP86-14 DOES A SECOND CONFIRMATORY PSA ABOVE 4.0NG/ML LEAD TO THE DIAGNOSIS OF MORE CLINICALLY SIGNIFICANT PROSTATE CANCER?1. Establish independent SWOG operations at the Portland VA Medical Center. 2. Establish processes that enable site to maintain accrual goals for site through life of project...
nPSA is a strong independent predictor of freedom from PSA failure and PFS in patients with low and intermediate-risk localized prostate cancer treated with RT alone. Longer follow-up and larger patient numbers are required to confirm these observations. 展开 ...
Results were not altered upon stratifying the sample between men who developed prostate cancer during the course of the study and those who did not.Results from this study indicate that chronic use of aspirin, other NSAIDs, or statins did not affect PSA levels or PSAV in men at high risk ...
It also may make other medications stop working, including some that are used to treat cancerorHIVinfection or to prevent organ rejection after transplant. If taken with an SSRI drug, St John's wort can cause a potentially dangerous condition called serotonin syndrome. The combination is not rec...
But a PSA test can still discover prostate cancer, leading to unnecessary tests and treatment. "You'll always find people who are convinced that no matter what is done, the evidence doesn't matter and what they really want to find out is if they have any cancer," Miller said. "They wi...
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predic- tive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008;26: 835-41....
Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity-the two highest quality studies identified do find prostate cancer-related mor- tality reductions. Evid Based Med 2011;16:20-1....
Prostate Cancer: Does PSA screening do more harm than good?doi:10.1038/nrurol.2009.63FarleySuzanne J.OAINature Reviews Urology
In conclusion, an effect of PSA testing on the natural history of prostate cancer is not yet fact, as determined by a randomised controlled trial, but it is certainly more than fiction.doi:10.1016/S1569-9056(02)00047-7John AndersonEuropean Urology Supplements...